Cristina Zuccato

List of Publications by Year
in descending order

44	936	471061 17	476904 29
papers	citations	h-index	g-index

45	45	45	1061
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Teaching during COVID-19 pandemic in practical laboratory classes of applied biochemistry and pharmacology: A validated fast and simple protocol for detection of SARS-CoV-2 Spike sequences. PLoS ONE, 2022, 17, e0266419.	1.1	2
2	Expression of Î³-globin genes in Î²-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin). Therapeutic Advances in Hematology, 2022, 13, 204062072211006.	1.1	16
3	Sex-specific transcriptional profiles identified in Î²-thalassemia patients. Haematologica, 2021, 106, 1207-1211.	1.7	5
4	Efficient CRISPR-Cas9-based genome editing of Î²-globin gene on erythroid cells from homozygous Î²039-thalassemia patients. Molecular Therapy - Methods and Clinical Development, 2021, 21, 507-523.	1.8	28
5	Treatment of Erythroid Precursor Cells from Î²-Thalassemia Patients with Cinchona Alkaloids: Induction of Fetal Hemoglobin Production. International Journal of Molecular Sciences, 2021, 22, 13433.	1.8	16
6	Discovery of Novel Fetal Hemoglobin Inducers through Small Chemical Library Screening. International Journal of Molecular Sciences, 2020, 21, 7426.	1.8	1
7	Surface plasmon resonance based analysis of the binding of LYAR protein to the rs368698783 (G>A) polymorphic AÎ³-globin gene sequences mutated in Î²-thalassemia. Analytical and Bioanalytical Chemistry, 2019, 411, 7699-7707.	1.9	1
8	Development and characterization of cellular biosensors for HTS of erythroid differentiation inducers targeting the transcriptional activity of Î³-globin and Î²-globin gene promoters. Analytical and Bioanalytical Chemistry, 2019, 411, 7669-7680.	1.9	2
9	BCL11A mRNA Targeting by miR-210: A Possible Network Regulating Î³-Globin Gene Expression. International Journal of Molecular Sciences, 2017, 18, 2530.	1.8	36
10	An AÎ³-globin G->A gene polymorphism associated with Î²039 thalassemia globin gene and high fetal hemoglobin production. BMC Medical Genetics, 2017, 18, 93.	2.1	16
11	A validated cellular biobank for Î²-thalassemia. Journal of Translational Medicine, 2016, 14, 255.	1.8	25
12	Orphan Drugs and Potential Novel Approaches for Therapies of Î²-Thalassemia: Current Status and Future Expectations. Expert Opinion on Orphan Drugs, 2016, 4, 299-315.	0.5	2
13	Structural and Functional Insights on an Uncharacterized AÎ³-Globin-Gene Polymorphism Present in Four Î²0-Thalassemia Families with High Fetal Hemoglobin Levels. Molecular Diagnosis and Therapy, 2016, 20, 161-173.	1.6	17
14	Increase of microRNA-210, Decrease of Raptor Gene Expression and Alteration of Mammalian Target of Rapamycin Regulated Proteins following Mithramycin Treatment of Human Erythroid Cells. PLoS ONE, 2015, 10, e0121567.	1.1	28
15	Recent trends in the gene therapy of β-thalassemia. Journal of Blood Medicine, 2015, 6, 69.	0.7	76
16	Generation and Characterization of a Transgenic Mouse Carrying a Functional HumanÎ²-Globin Gene with the IVSI-6 Thalassemia Mutation. BioMed Research International, 2015, 2015, 1-20.	0.9	2
17	Erythroid differentiation ability of butyric acid analogues: Identification of basal chemical structures of new inducers of foetal haemoglobin. European Journal of Pharmacology, 2015, 752, 84-91.	1.7	6
18	Induction of erythroid differentiation and increased globin mRNA production with furocoumarins and their photoproducts. Journal of Photochemistry and Photobiology B: Biology, 2013, 121, 57-66.	1.7	10

#	Article	IF	Citations
19	Tobramycin is a suppressor of premature termination codons. Journal of Cystic Fibrosis, 2013, 12, 806-811.	0.3	14
20	Combining gene therapy and fetal hemoglobin induction for treatment of Î²-thalassemia. Expert Review of Hematology, 2013, 6, 255-264.	1.0	15
21	Resveratrol: Antioxidant activity and induction of fetal hemoglobin in erythroid cells from normal donors and Î²-thalassemia patients. International Journal of Molecular Medicine, 2012, 29, 974-82.	1.8	39
22	Involvement of miRNA in erythroid differentiation. Epigenomics, 2012, 4, 51-65.	1.0	54
23	A combined approach for Î²-thalassemia based on gene therapy-mediated adult hemoglobin (HbA) production and fetal hemoglobin (HbF) induction. Annals of Hematology, 2012, 91, 1201-1213.	0.8	21
24	Erythroid Induction of Chronic Myelogenous Leukemia K562 Cells Following Treatment with a Photoproduct Derived from the UVâ€A Irradiation of 5â€Methoxypsoralen. ChemMedChem, 2010, 5, 1506-1512.	1.6	6
25	Synthesis and Cellular Pharmacology Studies of a Series of 2-amino-3-aroyl-4-substituted Thiophene Derivatives. Medicinal Chemistry, 2010, 6, 329-343.	0.7	5
26	Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for Identification of Drugs for the Treatment of Î²-Thalassemia and Sickle-Cell Anemia. Evidence-based Complementary and Alternative Medicine, 2009, 6, 141-151.	0.5	59
27	Production of Î²â€globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous Î²⁰39 thalassemia patients. American Journal of Hematology, 2009, 84, 720-728.	2.0	30
28	Increase in Î³-globin mRNA content in human erythroid cells treated with angelicin analogs. International Journal of Hematology, 2009, 90, 318-327.	0.7	26
29	Differentiation and Apoptosis in UVAâ€Irradiated Cells Treated with Furocoumarin Derivatives. Annals of the New York Academy of Sciences, 2009, 1171, 334-344.	1.8	17
30	Development of K562 cell clones expressing Î²â€globin mRNA carrying the Î²⁰39 thalassaemia mutation for the screening of correctors of stopâ€codon mutations. Biotechnology and Applied Biochemistry, 2009, 54, 41-52.	1.4	15
31	Bergamot (Citrus bergamia Risso) Fruit Extracts as Î³-Globin Gene Expression Inducers: Phytochemical and Functional Perspectives. Journal of Agricultural and Food Chemistry, 2009, 57, 4103-4111.	2.4	28
32	Expression of miR-210 during erythroid differentiation and induction of Î³-globin gene expression. BMB Reports, 2009, 42, 493-499.	1.1	82
33	Bis-epoxyethyl derivatives of distamycin A modified on the amidino moiety: induction of production of fetal hemoglobin in human erythroid precursor cells. International Journal of Molecular Medicine, 2009, 23, 105-11.	1.8	2
34	Furocoumarins photolysis products induce differentiation of human erythroid cells. Journal of Photochemistry and Photobiology B: Biology, 2008, 92, 24-28.	1.7	9
35	Induction of Î³-globin mRNA, erythroid differentiation and apoptosis in UVA-irradiated human erythroid cells in the presence of furocumarin derivatives. Biochemical Pharmacology, 2008, 75, 810-825.	2.0	39
36	A Novel Frameshift Mutation (+A) at Codon 18 of the Î²-Globin Gene Associated with High Persistence of Fetal Hemoglobin Phenotype and Î²-Thalassemia. Acta Haematologica, 2008, 119, 28-37.	0.7	9

#	Article	IF	Citations
37	Structure and Biological Activity of Furocoumarins. , 2007, , 265-276.		25
38	Everolimus Is a Potent Inducer of Erythroid Differentiation and Î³-Globin Gene Expression in Human Erythroid Cells. Acta Haematologica, 2007, 117, 168-176.	0.7	41
39	Effects on erythroid differentiation of platinum(II) complexes of synthetic bile acid derivatives. Bioorganic and Medicinal Chemistry, 2006, 14, 5204-5210.	1.4	16
40	Preparation and biological evaluation of some 1,2-O-isopropylidene-d-hexofuranose esters. Carbohydrate Research, 2006, 341, 538-544.	1.1	4
41	Effects of rapamycin on accumulation of ?-, ?- and ?-globin mRNAs in erythroid precursor cells from ?-thalassaemia patients. European Journal of Haematology, 2006, 77, 437-441.	1.1	83
42	Bis-epoxyethyl derivatives of distamycin A modified on the amidino moiety: Induction of production of fetal hemoglobin in human erythroid precursor cells. International Journal of Molecular Medicine, 1998, 23, 105.	1.8	2
43	A Rational Approach to Drug Repositioning in Î²-thalassemia: Induction of Fetal Hemoglobin by Established Drugs. Wellcome Open Research, 0, 7, 150.	0.9	2
44	A Rational Approach to Drug Repositioning in Î²-thalassemia: Induction of Fetal Hemoglobin by Established Drugs. Wellcome Open Research, 0, 7, 150.	0.9	2